Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • CDSCO Committee...

    CDSCO Committee rejects proposal for additional Indications of Dapaglofizin

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-05-05T12:52:44+05:30  |  Updated On 17 Aug 2021 11:56 AM IST

    New Delhi: British-Swedish multinational drugmaker, AstraZeneca's stride to win approval from the Indian drug regulators for the additional indications of its drug Dapagliflozin in worsening heart failure and nephropathy in the strength of 5mg and 10mg has been rejected by the Central Drugs Standard Control Organization (CDSCO) Committee.


    The SEC Committee declining the nod asked the firm to submit the regulatory approval status from other countries.


    Dapagliflozin, sold under the brand name Farxiga among others, is a medication used to treat type 2 diabetes. It is from the gliflozin class. It was developed by Bristol-Myers Squibb in partnership with AstraZeneca.


    In India, the drug is also sold by top pharma giants including Abbott and Sun Pharmaceutical Ltd who sell it under the brand names Gledepa 10 mg Tab and Oxra 10 mg Tab respectively.


    Dapagliflozin has been introduced as anti-diabetic medication. It works by removing excess sugar from your body through urine.


    Recently, AstraZeneca has proposed to the regulators in India for Dapagliflozin film-coated tablet in the strength of 5mg and 10mg for additional indication including the prevention of new or worsening heart failure or cardiovascular death and the prevention of new or worsening nephropathy.


    However, the committee noted that the proposal of the firm for the additional indication is not yet approved in any country. Also, there is no data for 5mg strength of the drug or Fixed Dose Combination (FDC) with Metformin for the said claims.


    After detailed deliberation, the SEC committee of CDSCO rejected the proposal recommending that the firm should submit the regulatory approval status from other countries and revise their proposal in respect of the strength of the drug and FDCs and indication in line with the outcomes of the study.


    The firm's current proposal for additional indication is based on the outcome of a global clinical trial study (A Phase IIIb, multicentre, randomised, double-blind, placebo-controlled trial to evaluate the effect of Dapagliflozin 10mg once daily on the Incidence of Cardiovascular death, Myocardial Infarction, or Ischemic stroke in patients with type 2 Diabetes (DECLARED1693C00001) conducted by AstraZeneca, in which India was one of the participating countries with 193 Indian patients.


    Prior to this, in 2012, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion on the drug.


    Also Read: AstraZeneca ties up with Transgene to develop viral immunotherapies

    AbbottAstraZenecablood sugarBristol-Myers SquibbCardiovascularcardiovascular deathCDSCOCHMPDapagliflozindiabetesFarxigaFixed Dose CombinationGledepaheart attackheart failureischemic strokeMetforminMetformin FDCmyocardial infarctionOxrasugarSun Pharmatype-2 diabetes
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok